Nitroglicerină Zentiva S.A. (Glyceryl Trinitrate)

After oral absorption, glyceryl trinitrate is converted to nitric oxide in vascular smooth‑muscle cells. Nitric oxide stimulates soluble guanylate cyclase, raising cyclic GMP levels, which relaxes smooth muscle in veins and arteries. This reduces preload and afterload, decreasing myocardial oxygen consumption and alleviating ischemic chest pain.

The specific dose of Nitroglicerină Zentiva is determined by the prescribing clinician based on the patient’s condition, response, and tolerance. Dosage forms may include tablets, sublingual sprays or other oral preparations, and the prescriber will set the appropriate regimen.

Safety data for glyceryl trinitrate during pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To request Nitroglicerină Zentiva, submit an enquiry on the product page at gnhindia.com indicating the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Glyceryl trinitrate belongs to the nitrate class, providing rapid relief of angina through vasodilation. Compared with beta‑blockers or calcium‑channel blockers, nitrates act directly on vascular smooth muscle and are useful for acute episodes, whereas other classes are often used for long‑term rate control. Choice depends on patient profile and therapeutic goals.

Store Nitroglicerină Zentiva at room temperature, below 25 °C, in its original packaging. Protect the product from moisture, excessive heat and direct sunlight to maintain stability and potency.

The medication is taken orally as prescribed. Depending on the formulation, it may be swallowed as a tablet, placed under the tongue as a sublingual tablet or spray, or used as an oral solution. Patients should follow the specific instructions provided by their healthcare professional.

Serious adverse events include severe hypotension that can lead to syncope, myocardial infarction in patients with unstable coronary disease, and rare cases of methemoglobinemia. Prompt medical attention is required if any of these symptoms occur.

Contraindications include patients with severe hypotension, recent myocardial infarction, increased intracranial pressure, severe anemia, or those taking phosphodiesterase‑5 inhibitors (e.g., sildenafil). Clinicians should also avoid use in patients with known hypersensitivity to nitrates.